Pharmacy Benefits Management – Page 22 – Global Reach Health

January 11, 2023

FDA Approves Airsupra (albuterol/budesonide) Metered-Dose Inhaler to Reduce
the Risk of Asthma Exacerbations

January 11, 2023 - Airsupra (albuterol/budesonide), formerly known as PT027, has been approved in the US for the as-needed treatment or prevention

January 6, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2021/03/FDA-HQ-480x360.jpg" class="scale-with-grid wp-post-image" alt="FDA-HQ" decoding="async" />

FDA-HQ

FDA approves Leqembi™ (Lecanemab–IRMB) under the accelerated approval
pathway for the treatment of Alzheimer’s disease

January 6, 2023 - The U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb)

January 3, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-480x360.jpg" class="scale-with-grid wp-post-image" alt="Cardiopulmonary-Bypass-for-Infants" decoding="async" srcset="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-480x360.jpg 480w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_300/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-300x225.jpg 300w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_768/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-768x576.jpg 768w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_195/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-195x146.jpg 195w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_50/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-50x38.jpg 50w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_100/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants-100x75.jpg 100w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_800/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Cardiopulmonary-Bypass-for-Infants.jpg 800w" sizes="(max-width:767px) 480px, 480px" />

Cardiopulmonary-Bypass-for-Infants

Methylprednisolone No Benefit in Cardiopulmonary Bypass for Infants

Jan. 3, 2023 -- Prophylactic use of methylprednisolone does not reduce the likelihood of a worse outcome for infants undergoing surgery with cardiopulmonary bypass

January 3, 2023

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2023/01/Occurrence-of-Cardiovascular-1-480x360.jpg" class="scale-with-grid wp-post-image" alt="Occurrence-of-Cardiovascular" decoding="async" />

Occurrence-of-Cardiovascular

Occurrence of Cardiovascular Events, Death Compared Between Thiazides

Jan. 3, 2023 - For patients receiving thiazide diuretics, the occurrence of major cardiovascular outcome events or non-cancer-related deaths is no lower

December 31, 2022

Brand Medications with Generic Alternatives Approved in
December, 2022

December, 2022 - Generic for Treanda - Bendamustine Hydrochloride Lyophilized Powder for Injection 25 mg/vial and 100 mg/vial

December 30, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-480x360.jpg" class="scale-with-grid wp-post-image" alt="Treating-Hypercalcemia-of-Malignancys" decoding="async" srcset="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-480x360.jpg 480w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_300/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-300x225.jpg 300w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_768/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-768x576.jpg 768w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_195/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-195x146.jpg 195w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_50/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-50x38.jpg 50w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_100/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys-100x75.jpg 100w, https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_840/https://www.globalreachhealth.com/wp-content/uploads/2022/12/Treating-Hypercalcemia-of-Malignancys.jpg 840w" sizes="(max-width:767px) 480px, 480px" />

Treating-Hypercalcemia-of-Malignancys

Recommendations Developed for Treating Hypercalcemia of Malignancy

Dec. 30, 2022 - In a clinical practice guideline issued by the Endocrine Society and published online Dec. 21 in the Journal of Clinical Endocrinology

December 28, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/12/mri-for-the-evaluation-of-lung-ventilation-480x360.jpg" class="scale-with-grid wp-post-image" alt="mri-for-the-evaluation-of-lung-ventilation" decoding="async" />

mri-for-the-evaluation-of-lung-ventilation

FDA approves Xenoview (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation

December 28, 2022 - Polarean Imaging plc, the medical imaging technology company, announces that the U.S. Food and Drug Administration

December 28, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/12/relapsing-forms-480x360.jpg" class="scale-with-grid wp-post-image" alt="relapsing-forms" decoding="async" />

relapsing-forms

Briumvi (ublituximab-xiiy) is approved for the treatment of relapsing forms of
multiple sclerosis

December 28, 2022 – TG Therapeutics, Inc. has announced the U.S. Food and Drug Administration (FDA) has approved Briumvi^TM (ublituximab-xiiy) for the treatment